Here's Why Rigel Pharmaceuticals Jumped Another 17% Today

What happened

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) closed up 17% on Thursday as investors further digested the company's update on Wednesday.

So what

The business update, as the company called it, had a bit of everything.

Rigel disclosed preliminary third-quarter sales of $11.7 million for Tavalisse, its treatment for a blood disorder called chronic immune thrombocytopenia (ITP). That sales number represented a 15% increase over the second quarter. Rigel estimates that the U.S. ITP market is about $1 billion, so it has plenty of potential for further growth.

Doctor talking to a patient in an exam room

Image source: Getty Images.

On the pipeline front, Rigel noted that it completed a phase 1 study for R835, which inhibits a protein involved in the inflammatory response. The study was in healthy subjects but included a lipopolysaccharide challenge that induced an immune response -- measured with biomarkers -- in subjects given placebo, which was dampened in subjects given R835. Rigel is still contemplating which disease to test R835 in first.

Rigel also disclosed a new pipeline drug candidate, R552, which targets a protein involved in neurodegenerative and immune-mediated diseases. The company is testing R552 in a phase 1 study and is working on a follow-on candidate that will work in the central nervous system for neurodegenerative diseases.

Now what

The pipeline updates are nice, but the near-term value for Rigel is clearly tied to Tavalisse. A 15% quarter-over-quarter increase is substantial, but it's working off a low base. Rigel is pretty cheap for a biotech. With a market cap under $350 million, there isn't too much growth priced in.

In addition to growing sales in the U.S., Tavalisse is likely to gain approval in Europe after a positive preliminary vote by EU regulators. A final vote is expected next month, which could set up a rollout in Europe through its partner Grifols starting in 2020.

10 stocks we like better than Rigel Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Rigel Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More